Benazepril in severe CKD
Trial question
What is the role of benazepril in patients without diabetes who had advanced renal insufficiency?
Study design
Single center
Double blinded
RCT
Population
Characteristics of study participants
50.0% female
50.0% male
N = 224
224 patients (113 female, 111 male).
Inclusion criteria: patients without diabetes who had advanced renal insufficiency.
Key exclusion criteria: immediate need for dialysis; treatment with corticosteroids, non-steroidal anti-inflammatory drugs or immunosuppressive drugs; renovascular disease; MI; connective-tissue disease; obstructive uropathy.
Interventions
N=112 benazepril (20 mg per day).
N=112 placebo (matching placebo per day).
Primary outcome
Death, end-stage renal disease, or doubling of serum creatinine
41%
60%
60.0 %
45.0 %
30.0 %
15.0 %
0.0 %
Benazepril
Placebo
Significant
decrease ▼
NNT = 5
Significant decrease in death, ESRD, or doubling of the serum creatinine (41% vs. 60%; RR 0.68, 95% CI 0.22 to 1.14).
Secondary outcomes
Significant increase in the percentage of patients achieving a reduction in proteinuria (52% vs. 20%; RR 2.6, 95% CI 1.06 to 4.14).
Safety outcomes
No significant difference in major adverse events.
Conclusion
In patients without diabetes who had advanced renal insufficiency, benazepril was superior to placebo with respect to death, ESRD, or doubling of the serum creatinine.
Reference
Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40.
Open reference URL